Nadege Carrie

Toulouse, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

The transcription factor Eomes drives a stemness program in CD4+ T cells that promotes anti-tumor immunity in response to immunotherapy.

Journal: Immunity
Published: January 21, 2025

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma.

Journal: Blood
Published: July 10, 2024

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

Journal: Blood
Published: December 06, 2023

TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation.

Journal: Immunity
Published: June 29, 2022

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.

Journal: Blood
Published: May 06, 2021

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy.

Journal: Immunity
Published: September 25, 2019

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma.

Journal: Blood
Published: January 04, 2018

In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.

In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.

Journal: Brain : a journal of neurology
Published: October 12, 2015

Foxo3 Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes.

Foxo3 Transcription Factor Drives Pathogenic T Helper 1 Differentiation by Inducing the Expression of Eomes.

Journal: Immunity
Published: March 17, 2015

Bispecificity for myelin and neuronal self-antigens is a common feature of CD4 T cells in C57BL/6 mice.

Bispecificity for myelin and neuronal self-antigens is a common feature of CD4 T cells in C57BL/6 mice.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 20, 2014

Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model.

Tc17 CD8+ T cells potentiate Th1-mediated autoimmune diabetes in a mouse model.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 21, 2012

T cell apoptosis and induction of Foxp3+ regulatory T cells underlie the therapeutic efficacy of CD4 blockade in experimental autoimmune encephalomyelitis.

T cell apoptosis and induction of Foxp3+ regulatory T cells underlie the therapeutic efficacy of CD4 blockade in experimental autoimmune encephalomyelitis.

Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: July 18, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026